NDA 022211 · Bausch and Lomb
Zirgan
Ganciclovir · Ophthalmic · Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral
OrphanLast checked: Nov 20, 2026Latest source record: Jan 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Sep 15, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
196
46 Phase 3, 21 recruiting
FAERS reports
10,361
9,837 serious, 3,155 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ( 1 )
Mechanism: ZIRGAN is an antiviral drug [ see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZIRGAN · GANCICLOVIR 0.15% · GEL, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ganciclovir" as an intervention, any sponsor and status, largest first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001034 · 850 participants
Drug: Ganciclovir · For: Cytomegalovirus Retinitis; HIV Infections; Gastrointestinal Diseases
Sites: San Francisco, California; Denver, Colorado; Wilmington, Delaware · 17 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002095 · 700 participants
Drug: Ganciclovir · For: Cytomegalovirus Infections; HIV Infections
Sites: Berkeley, California; Los Angeles, California; San Diego, California · 19 sites in all
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03443869 · 601 participants · Start May 3, 2018 · Primary completion Apr 5, 2022
Drug: Letermovir; Valganciclovir and 4 more · For: CMV Disease
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 94 sites in all
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaPivotal-lookingCompleted
Hospital Universitario 12 de OctubreAcademic, hospital or other
NCT03915366 · 563 participants · Start Mar 1, 2020 · Primary completion Jan 31, 2025
Drug: Valganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents · For: Pneumonia; HIV/AIDS; Tuberculosis and 1 more
Sites: Abidjan, Côte d’Ivoire; Bourdeaux, France; Toulouse, France · 13 sites in all
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02927067 · 553 participants · Start Apr 14, 2017 · Primary completion Jul 1, 2022
Drug: Maribavir; Valganciclovir · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 129 sites in all
- Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by InjectionPivotal-lookingStatus unknown
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00017784 · 500 participants
Drug: Valganciclovir · For: Cytomegalovirus Retinitis; HIV Infections
Sites: Beverly Hills, California; Paramount, California; San Francisco, California · 9 sites in all
Roche Global DevelopmentRoche (Genentech) (RHHBY)
NCT00002134 · 450 participants
Drug: Ganciclovir · For: Cytomegalovirus Retinitis; HIV Infections
Sites: Beverly Hills, California; Irvine, California; Los Angeles, California · 23 sites in all
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06798909 · 360 participants (planned) · Start Jul 22, 2025 · Primary completion Nov 30, 2030
Drug: Valganciclovir (Pre-emptive CMV Therapy); Valganciclovir CMV Prophylaxis · For: Cytomegalovirus (CMV); Kidney Transplant; Complications; Kidney Diseases
Sites: San Francisco, California; Miami, Florida; Atlanta, Georgia · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,720
- drug ineffective1,484
- cytomegalovirus infection1,208
- drug resistance678
- pyrexia607
- product use in unapproved indication552
- neutropenia548
- pancytopenia525
- diarrhoea450
- cytomegalovirus viraemia434
- pneumonia429
- sepsis420
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 73 |
| 2005 | 76 |
| 2006 | 109 |
| 2007 | 124 |
| 2008 | 182 |
| 2009 | 226 |
| 2010 | 158 |
| 2011 | 260 |
| 2012 | 303 |
| 2013 | 214 |
| 2014 | 234 |
| 2015 | 237 |
| 2016 | 338 |
| 2017 | 501 |
| 2018 | 607 |
| 2019 | 935 |
| 2020 | 1,023 |
| 2021 | 938 |
| 2022 | 858 |
| 2023 | 850 |
| 2024 | 848 |
| 2025 | 799 |
| 2026 | 466 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zirgan (Ganciclovir)
2024 spending
$9.2M
Beneficiaries
11,054
18,703 claims
Per beneficiary
$834
$93.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,188,676 |
| 2021 | $8,521,746 |
| 2022 | $8,818,227 |
| 2023 | $9,445,994 |
| 2024 | $9,219,670 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, et al. · Clin Infect Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adenovirus diseases: a systematic review and meta-analysis of 228 case reports.
Gu J, Su QQ, Zuo TT, et al. · Infection 2021 · Meta-Analysis, Systematic Review
- Valganciclovir for symptomatic congenital cytomegalovirus disease.
Kimberlin DW, Jester PM, Sánchez PJ, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S, Alain S, Cervera C, et al. · J Infect Dis 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Vernooij RW, Michael M, Ladhani M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, et al. · Am J Transplant 2007 · Multicenter Study, Randomized Controlled Trial
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.